The growing use of next generation-sequencing to identify cancer-associated alterations as well as the increasing number of targeted drugs holds promise for better matching patients with cancer with effective therapies. The FoundationOne (F1; Foundation Medicine) test sequences clinical tumor samples to characterize the exons of 315 cancer-associated genes and introns from 28 genes involved in rearrangements. The Guardant360 (G360; Guardant Health) test uses cell-free circulating DNA from blood to sequence 70 genes. Both the F1 and G360 tests have high specificities (>99%) and somewhat lower sensitivities.
1,2 However, little is known about how different next-generation sequencing tests compare when used in the same patients with cancer. We compared reports from F1 and G360 testing in 9 patients from a community oncology practice to determine the level of concordance between the platforms. Results | The Table displays the clinical characteristics of the patients and reported alterations and drugs. One patient had no identified genetic alteration using either platform. The remaining 8 patients had 45 alterations, only 10 (22%) of which were concordant between the platforms. For 2 of these remaining 8 patients, there was no concordance among the described alterations. For these 8 patients, a total of 36 drugs were mentioned. However, only 9 drugs (25%) were recommended for the same patients by both platforms, and in 5 patients, there was no overlap between the drugs recommended by the F1 test and those recommended by the G360 test. Concordance among drugs improved to 8 of 13 (62%) when reported mutations were also concordant. We expected that relatively high-frequency alterations identified by G360 testing would be more likely captured in tumor tissues examined by F1 testing. Consistent with this expectation, discordant alterations in results of G360 testing were more likely to have variant allele frequencies less than 1% (19 of 20 mutations, with 2 mutations without reported variant allele frequencies), compared with concordant G360 alterations (4 of 9 mutations, with 1 mutation without reported vari- Abbreviations: F1, FoundationOne; G360, Guardant360. a A recommendation of other KIT proto-oncogene receptor tyrosine kinase inhibitors was counted as a single drug.
b The 67 alterations detectable owing to technical differences only by F1 testing were excluded from the analysis to avoid an exaggerated portrayal of discordance.
ant allele frequencies; P = .005) (Figure, A) and the distribution of variant allele frequencies was lower relative to concordant alterations (P = .02) (Figure, B) . However, concordance among alterations improved only slightly (to 5 of 18 [28%]) when comparisons were limited to variant allele frequencies of 1% or more.
Discussion | Our findings indicate that the output from genetic testing can differ markedly depending on which genetic test is applied. Since both the F1 and the G360 tests are performed in thousands of patients with cancer each year, these findings are clinically relevant. A major cause of discordance beyond that described here is that F1 testing detects a much broader range of aberrations than that accommodated by G360 testing. However, we excluded the alterations that are unique to F1 testing from our analysis; therefore, the discordance we describe comes from other causes. Differences in timing between the 2 tests may cause discordance; however, 7 of the 8 patients with alterations underwent both tests within a 2½-month period. Tumor heterogeneity 3 and differences in the processes used to determine whether a variant is reported are also likely contributors to discordance. Although reports from G360 testing frequently include relatively low-frequency variants, many alterations are likely present in only a small fraction of tumor cells, as supported by our finding that discordance between F1 and G360 testing declines after restricting comparisons to variants found via G360 testing present at frequencies of greater than 1%.
Although these results are preliminary, significant discordance also has been noted between reports comparing tissuebased next-generation sequencing tests 4,5 and, in a recent report, between results from F1 and G360 testing. 6 Our findings indicate that in-depth comparisons of next-generation sequencing tests across larger numbers of patients with cancer are needed to improve concordance and clinical utility. 
Odontoma in a 255-Million-Year-Old Mammalian Forebear
Distinctive mammalian traits, such as endothermy (warmbloodedness), a muscular diaphragm, large brain size, fur, and a highly specialized dentition, including diphyodonty, prismatic enamel, and a functionally regionalized tooth row (heterodonty), are the product of more than 300 million years of evolutionary divergence from reptiles and other tetrapods. 1 The sequence and timing of these adaptations are captured in the fossil record of premammalian synapsids (Figure 1 ), but an understanding of the evolutionary context of mammalian disease, including cancer, remains elusive. We report the first instance, to our knowledge, of a tumor in a 255-million-yearold mammalian forebear and comment on the implications for establishing the phylogenetic and physiological conditions under which such pathologic features first arose.
Methods | Fossil thin-sectioning protocol is well established, and the resultant data are an increasingly significant tool in understanding the physiologic mechanisms and evolution of extinct animals. 2 Despite the relative abundance of gorgonopsian fossils, few histologic observations have been made of their jaws. The anterior right dentary of a gorgonopsian was prepared by embedding the specimen in a clear polyester resin. Thin (approximately 2 cm) wafers of the embedded specimen were cut using a precision slow-speed saw and then mounted onto glass slides. Sections were ground to a final thickness of approximately 100 μm using a variable-speed grinder and polisher. The root of the lower canine and associated pathological tissues were examined and imaged under regular and cross-polarized light. Institutional review board approval was waived for this study because no live specimens were used.
Results | Histologic sections present ectopic toothlike structures that were not apparent from the external morphologic features of the mandible (Figure 2) . The lesions are located adjacent to the labial edge of the functional canine root, and each resembles a miniature tooth with an internal cavity, dentine as evidenced by the presence of tubules, and a thin outer covering of enamel. Up to 8 lesions of varying diameter (approximately 0.3-3.9 mm) can be observed on an individual slide, with consecutive slides revealing that their shape and arrangement change along the apical-cervical axis of the canine root. Apically, the lesions are circular and cluster around the mesial edge of the canine root. Incursion of the lesions into the root of the canine coincides with the loss of cementum and dentine in the latter. Moving cervically, the masses erode even further into the functional tooth root. Midroot, some of the lesions lose their circular cross-sectional shape and become more amorphous, although continuing to maintain similar tissues and tissue boundaries. Near the cervical region of the canine root, the lesions slightly retreat from their incursion and penetrate further into the bone of the jaw. At this cervical end, the pathologic features return to a circular cross-section and cluster together. The mammalian and reptilian lines diverged approximately 320 million years ago, with the group that included extant mammals appearing approximately 165 million years ago. Gorgonopsians (in blue) lacked many canonical mammalian features, such as large brain size, diphyodonty, distinct thoracic and lumbar vertebrae, and 3 middle ear ossicles, which evolved later along the lineage marked 1. Odontomas have been recognized in the groups indicated by stars (gorgonopsians, humans, horses, mammoths, and deer).
